CDKN2A and lung cancer: Two of them, cyclin-dependent kinase inhibitor 2A (CDKN2A), which encodes the tumor suppressor p16, and O-6-methylguanine-DNA methyltransferase (MGMT), are methylation targets shared by COPD and lung cancer [83,84].